ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"
|ClinicalTrials.gov Identifier: NCT00360386|
Recruitment Status : Completed
First Posted : August 4, 2006
Last Update Posted : August 31, 2010
- To compare the Kinetics of inhibition of platelet aggregation (aggregometry) and platelet activation (flow cytometry) with different loading doses of clopidogrel
- To evaluate the effect on various parameters of inflammation and necrosis and the safety of these loading doses
|Condition or disease||Intervention/treatment||Phase|
|Ischemia||Drug: Clopidogrel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||February 2005|
|Actual Study Completion Date :||February 2005|
- Maximum intensity of platelet aggregation induced by ADP 5 µmol/L.
- Kinetic profile by aggregometry. Kinetic profile of platelet activation by flow cytometry - Inflammation parameters/markers of necrosis. Death, myocardial infarction, ischemic recurrences leading to revascularisation and/or rehospitalisation.Safety.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00360386
|Study Director:||SAGNARD Luc||Sanofi|